• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Biomea Fusion Inc (NQ: BMEA )

    10.75 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 10.75
    Bid (Size) 10.25 (3)
    Ask (Size) 11.20 (1)
    Prev. Close 10.75
    Today's Range 10.75 - 10.75
    52wk Range 8.125 - 43.69
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    BMEA Stock Earnings: Biomea Fusion Misses EPS for Q4 2023
    BMEA stock results show that Biomea Fusion missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace

    Performance

    YTD
    -26.72%
    -26.72%
    1 Month
    -29.74%
    -29.74%
    3 Month
    -40.41%
    -40.41%
    6 Month
    -2.80%
    -2.80%
    1 Year
    -66.10%
    -66.10%

    More News

    Read More
    Recap: Biomea Fusion Q4 Earnings
    Via Benzinga
    Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    What's Going On With Biomea Fusion Stock?
    Via Benzinga
    Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
    Via InvestorPlace
    Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Feeling Shut Out? 3 Sizzling Stocks and the Pull-Back Prices to Watch For
    Via InvestorPlace
    3 Speculative Stocks That Could Make Your February Unforgettable
    Via InvestorPlace
    3 Long-Term Stocks to Buy on the Dip: February 2024
    Via InvestorPlace
    Alaska Air Posts Upbeat Earnings, Joins Xerox, United Rentals And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Jim Cramer Says Move On From This Energy Stock: 'It's Moved Too Much'
    Via Benzinga
    Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.